MIAMI, Sept. 13 – Incyte Genomics (Nasdaq: INCY) said Wednesday it planned to create a new revenue stream by offering exclusive licenses to pharmaceutical companies for its “deep SNP” genotyping data, which will link single-nucleotide differences to specific diseases.

“Deep SNPs would be a different business model,” Incyte CEO Roy Whitfield told GenomeWeb. “It will be on an exclusive basis with high royalties.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.